Spezifische immuntherapie bei kindern und jugendlichen

Translated title of the contribution: Specific immunotherapy in childhood and adolescence

Matthias Kopp, Frank Friedrichs, Bodo Niggemann*

*Corresponding author for this work


The clinical efficacy of subcutaneous specific immunotlierapy (SCIT) has been confirmed in many studies. SCIT is the only specific treatment of allergic disorders with documented long-term efficacy after termination. Based on the observation, that allergens are the main trigger factors of atopic diseases in childhood (e.g., in bronchial asthma and allergic rhinitis), the use of specific immunotherapy (SIT) should be considered at an early stage of the disease. Furthermore, clinical studies suggest that SIT alters the natural course of allergy in monosensitized children in preventing the development of new sensitizations.

Translated title of the contributionSpecific immunotherapy in childhood and adolescence
Original languageGerman
JournalAllergo Journal
Issue number3
Pages (from-to)228-232
Number of pages5
Publication statusPublished - 04.2008

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)


Dive into the research topics of 'Specific immunotherapy in childhood and adolescence'. Together they form a unique fingerprint.

Cite this